FES BPET-DBT in Newly Diagnosed Breast Cancer
Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Dec 12, 2022
Trial Information
Current as of January 16, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new imaging technique for women who have recently been diagnosed with breast cancer that is positive for estrogen receptors (ER positive). To participate, patients must be at least 18 years old and have at least one breast lesion that is 1.0 cm or larger, which can be seen on standard imaging tests like a mammogram or ultrasound. The study will involve up to 20 women who will receive an intravenous injection of a special substance called \[18F\]-Fluoroestradiol (FES) before undergoing advanced imaging with a device that combines two types of breast imaging: Positron Emission Tomography (PET) and Digital Breast Tomosynthesis (DBT). This imaging will help researchers learn more about how the cancer behaves, but it will not influence treatment decisions, which will be based on traditional imaging results.
Eligible participants should not be pregnant or breastfeeding, and they should not be currently taking certain medications like tamoxifen or raloxifene. Before joining the study, women will need to give written consent, understanding that this is an investigational study. Throughout the trial, patients can expect to receive thorough explanations of the procedures and to be closely monitored for their safety. This study aims to enhance our understanding of breast cancer imaging and improve future treatments.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Participants will be ≥ 18 years of age.
- • 2. Known ER positive (by immunohistochemistry) breast cancer.
- • 3. At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. mammogram, ultrasound, MRI, CT, FDG-PET/CT). Only one type of imaging is required to show a lesion.
- • 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
- Exclusion Criteria:
- • 1. Females who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to PET imaging..
- • 2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
- • 3. Currently taking tamoxifen or raloxifene
- • 4. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Trial Officials
Christine Edmonds, MD
Principal Investigator
Abramson Cancer Center at Penn Medicine
About Abramson Cancer Center At Penn Medicine
The Abramson Cancer Center at Penn Medicine is a leading academic institution dedicated to advancing cancer research, treatment, and prevention. As part of the University of Pennsylvania, the center integrates cutting-edge scientific discovery with comprehensive clinical care, offering patients access to innovative therapies and clinical trials. Renowned for its multidisciplinary approach, the Abramson Cancer Center collaborates with experts across various specialties to deliver personalized treatment plans while fostering a supportive environment for patients and their families. Committed to improving outcomes and quality of life for cancer patients, the center is at the forefront of groundbreaking research initiatives and educational programs aimed at transforming cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials